EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants

Romain Sechaud, Helen Gu, Gholamreza Rahmanzadeh, Ovidiu Chiparus, Astrid Breitschaft, Hans D Menssen

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04683-3 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Romain Sechaud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, CH-4002, Switzerland. romain.sechaud@novartis.com. Hauptthemen laut MEDLINE: Drug Interactions, Staurosporine, Cytochrome P-450 CYP2D6, ATP Binding Cassette Transporter, Subfamily G, Member 2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsStaurosporineCytochrome P-450 CYP2D6ATP Binding Cassette Transporter, Subfamily G, Member 2DextromethorphanNeoplasm ProteinsDigoxinRosuvastatin CalciumHumansAdultMaleFemaleMiddle AgedATP Binding Cassette Transporter, Subfamily B, Member 1Young AdultHealthy Volunteers

Stichwörter der Autor:innen

BCRPCYP2D6DextromethorphanDigoxinDrug–drug interactionMidostaurinP-gpRosuvastatin

Substanzen

midostaurinStaurosporineCytochrome P-450 CYP2D6ATP Binding Cassette Transporter, Subfamily G, Member 2DextromethorphanNeoplasm ProteinsABCG2 protein, humanDigoxinRosuvastatin CalciumATP Binding Cassette Transporter, Subfamily B, Member 1

Autor:innen und Institutionen

  • Novartis Pharma AG, Basel, CH-4002, Switzerland. romain.sechaud@novartis.com.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Novartis Pharma AG, Basel, CH-4002, Switzerland.
  • Parexel International GmbH-14050, Berlin, Germany.

Förderung

  • Novartis

Zitieren

APA

Sechaud, R., Gu, H., Rahmanzadeh, G., Chiparus, O., Breitschaft, A., & Menssen, H. D. (2024). Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04683-3

Vancouver

Sechaud R, Gu H, Rahmanzadeh G, Chiparus O, Breitschaft A, Menssen HD. Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04683-3

BibTeX
@article{Sechaud2024,
  author = {Sechaud, Romain and Gu, Helen and Rahmanzadeh, Gholamreza and Chiparus, Ovidiu and Breitschaft, Astrid and Menssen, Hans D},
  title = {Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04683-3}
}
Kostenlos starten →